Dermatology: What It Is and Why It Matters

Dermatology is the branch of medicine responsible for diagnosing and treating conditions affecting the skin, hair, nails, and adjacent mucous membranes — a scope that spans more than 3,000 distinct diseases according to the American Academy of Dermatology (AAD). This page provides a comprehensive reference on what dermatology covers, how the specialty is defined and regulated, where its boundaries lie, and why those boundaries carry real clinical and legal weight. The content draws on authoritative public sources and connects to a library of more than 50 in-depth articles covering conditions, procedures, training, insurance, and patient rights across the dermatology landscape.

Boundaries and Exclusions

The skin is the body's largest organ, covering approximately 1.7 square meters in the average adult (National Institutes of Health, MedlinePlus), yet dermatology does not operate without hard jurisdictional limits. The specialty addresses cutaneous manifestations of systemic diseases — lupus erythematosus producing a malar rash, for example — but systemic management of that underlying autoimmune disease falls to rheumatology. Similarly, ophthalmic surface conditions involving the conjunctiva are typically managed by ophthalmology, not dermatology, even when the two tissue types are adjacent.

Dermatology also draws a deliberate line between medical and cosmetic practice. Procedures performed solely for aesthetic enhancement without an underlying diagnosed condition — absent a clinical indication — occupy a distinct regulatory and reimbursement category. The Centers for Medicare and Medicaid Services (CMS) does not reimburse cosmetic-only procedures under standard Medicare Part B, and this exclusion shapes how practices structure billing and documentation (CMS, Medicare Benefit Policy Manual, Chapter 16).

Dermatopathology — the microscopic examination of skin tissue — is a subspecialty that can be practiced by pathologists who are not dermatologists. Board certification in dermatopathology is jointly administered by the American Board of Dermatology (ABD) and the American Board of Pathology, creating a credentialing overlap that is formally defined rather than ambiguous. Practitioners without either primary board certification may not legally represent themselves as dermatopathologists.

The Regulatory Footprint

Medical licensure for dermatologists in the United States is issued at the state level under authority of individual state medical practice acts. No single federal license governs clinical practice, though federal statutes reach deeply into the specialty through drug approval, device clearance, radiation safety, and laboratory standards.

The U.S. Food and Drug Administration (FDA) regulates every topical, systemic, and biologic medication used in dermatology through the drug approval pathway under 21 U.S.C. § 355. Biologics — including monoclonal antibodies used in psoriasis and atopic dermatitis treatment — are additionally governed under the Public Health Service Act, Section 351 (FDA, Biologics). Laser and energy-based devices undergo FDA premarket review under device classification rules in 21 CFR Parts 862–892.

Clinical laboratories performing skin biopsy analysis must comply with the Clinical Laboratory Improvement Amendments (CLIA), administered jointly by CMS, the FDA, and the Centers for Disease Control and Prevention (CDC). CLIA certification requirements apply regardless of whether the laboratory is hospital-based or operates within a private dermatology office.

Occupational exposure to skin-hazardous substances falls under OSHA standards, particularly 29 CFR 1910.1030 (bloodborne pathogens) and OSHA's general duty clause. The full regulatory context for dermatology is detailed in a dedicated reference page on this site.

What Qualifies and What Does Not

The ABD defines the clinical scope of dermatology as encompassing the structure and function of the skin and its appendages (hair, nails, sebaceous glands, sweat glands), the diagnosis and treatment of diseases affecting those structures, and the performance of skin surgery. This definition, codified in the ABD's published training requirements, creates the primary classification boundary.

Conditions that fall within dermatology's scope:

Conditions that do not fall within dermatology's primary scope:

The distinction between cosmetic and medical dermatology is a persistent source of classification complexity. Botulinum toxin injections used to treat hyperhidrosis (excessive sweating) carry a clinical ICD-10-CM code (L74.5) and qualify for medical billing; the same injections performed for facial line reduction do not. The ICD-10-CM coding system, maintained by the National Center for Health Statistics (NCHS), provides the operational classification layer that determines coverage eligibility.

Primary Applications and Contexts

Dermatology practice occurs across four broad clinical contexts, each with distinct patient populations, acuity levels, and procedural demands.

1. Ambulatory outpatient practice accounts for the largest share of dermatology encounters. The AAD reports that dermatologists conducted more than 40 million patient visits annually in the United States in recent published estimates. Acne, skin cancer screening, and eczema management dominate outpatient volume.

2. Procedural and surgical dermatology includes Mohs micrographic surgery — a tissue-sparing technique for skin cancer excision with published cure rates exceeding 99% for appropriately selected primary basal cell carcinomas (Skin Cancer Foundation) — as well as excisional biopsy, cryotherapy, laser treatment, and photodynamic therapy.

3. Inpatient and consultation dermatology serves hospitalized patients with severe or life-threatening cutaneous conditions: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythroderma, or severe drug eruptions. These conditions carry mortality rates that justify specialist involvement even in acute-care settings.

4. Teledermatology has expanded significantly as a delivery model. Store-and-forward teledermatology — transmitting clinical images for asynchronous review — is recognized as a distinct service modality by CMS and carries its own reimbursement codes under the telehealth provisions extended through federal legislative action.

How This Connects to the Broader Framework

Dermatology does not function in isolation from other medical specialties or from the administrative infrastructure that governs healthcare delivery in the United States. The specialty intersects with primary care through shared management of common conditions; with oncology through melanoma staging and systemic treatment; with allergy and immunology through patch testing and hypersensitivity disorders; and with rheumatology through skin manifestations of systemic disease.

At the level of public health infrastructure, dermatology intersects with the CDC's skin cancer prevention programming, the National Cancer Institute's SEER database (which tracks melanoma incidence), and the Environmental Protection Agency's (EPA) UV Index — a public communication tool that directly informs clinical guidance on photoprotection.

This site is part of the Authority Network America ecosystem (authoritynetworkamerica.com), which maintains reference-grade properties across health, legal, and technical domains. Within this ecosystem, dermatology content is organized to serve as an accessible yet authoritative reference for patients, researchers, and health professionals seeking to understand the clinical and regulatory landscape of skin medicine.

For broader orientation across the full scope of skin diseases, the skin conditions overview page provides a structured classification of dermatological conditions by category, mechanism, and treatment approach.

Scope and Definition

The American Board of Medical Specialties (ABMS) formally recognizes dermatology as one of 24 medical specialties in the United States. The ABD — the certifying body — was established in 1932 and is one of the oldest specialty boards in American medicine. As of publicly available ABD data, more than 13,000 dermatologists hold active ABD certification in the United States.

The specialty encompasses four formal subspecialties recognized through ABD certification or conjoint boards:

Subspecialty Certifying Authority Primary Focus
Dermatopathology ABD / American Board of Pathology Microscopic diagnosis of skin tissue
Pediatric Dermatology ABD (conjoint with American Board of Pediatrics) Skin disease in neonates, children, adolescents
Clinical and Laboratory Dermatological Immunology ABD Immunologic testing and autoimmune skin disease
Procedural Dermatology (fellowship, not a separate board) ACGME-accredited programs Advanced surgical and cosmetic procedures

Dermatology residency in the United States consists of a preliminary internship year (typically in internal medicine or surgery) followed by 3 years of Accreditation Council for Graduate Medical Education (ACGME)-accredited dermatology training, for a total minimum of 4 years post-medical school. Match data from the National Resident Matching Program (NRMP) consistently places dermatology among the most competitive specialties: in the 2023 Main Residency Match, dermatology had a fill rate of 100% with the majority of positions going to U.S. MD seniors (NRMP, 2023 Main Residency Match Data).

Why This Matters Operationally

Skin disease carries measurable economic and public health weight. The AAD has reported that skin conditions affect 1 in 3 Americans at any given time, and the annual cost of skin disease treatment in the United States has been estimated at more than $75 billion (AAD, Burden of Skin Disease). Melanoma, the deadliest form of skin cancer, accounts for the majority of skin cancer deaths despite representing only about 1% of skin cancer cases; the National Cancer Institute's SEER data places estimated new melanoma diagnoses at approximately 97,610 for 2023 (NCI SEER).

Delayed diagnosis of skin cancer types and warning signs carries documented consequences in stage at presentation and survival outcomes. The 5-year survival rate for localized melanoma exceeds 98%, but drops to approximately 35% for distant-stage disease at diagnosis (NCI SEER), illustrating the clinical urgency of early dermatologic evaluation.

Common conditions such as acne causes and treatment and eczema and atopic dermatitis generate substantial quality-of-life burden even when they are not life-threatening. Published research in the Journal of Investigative Dermatology has documented that atopic dermatitis affects approximately 16.5 million adults in the United States, with roughly 6.6 million experiencing moderate-to-severe disease. The development of biologic therapies — beginning with dupilumab's FDA approval in 2017 — reshaped the treatment landscape for this population.

Psoriasis types and management and rosacea diagnosis and care represent conditions where dermatology's intersection with cardiology, gastroenterology, and mental health is clinically significant: psoriasis is associated with elevated cardiovascular risk, and rosacea may share pathophysiologic pathways with gastrointestinal conditions.

For answers to foundational questions about the specialty, the dermatology frequently asked questions page addresses common points of confusion about scope of practice, insurance, and referral pathways.

What the System Includes

This reference site covers dermatology as a complete clinical and regulatory system rather than a collection of isolated condition descriptions. The content library spans more than 50 published pages organized across five functional domains:

Conditions and diagnosis — from common inflammatory conditions like eczema and atopic dermatitis to complex presentations like melanoma and autoimmune blistering disease. Each condition page addresses mechanism, classification, diagnostic criteria, and treatment categories without providing individualized clinical guidance.

Procedures and treatments — including biopsy, Mohs surgery, phototherapy, cryotherapy, topical and systemic medications, biologics, and laser-based interventions. Procedure pages address how each modality works, what regulatory framework governs it, and what classification distinctions exist between medical and cosmetic indications.

Practitioner and training framework — covering board certification, residency structure, subspecialty pathways, and the distinction between dermatologists and general practitioners managing skin complaints.

Regulatory and coverage context — addressing FDA drug and device oversight, CMS billing and reimbursement rules, CLIA laboratory standards, and state licensure frameworks. The operational checklist below summarizes the regulatory touchpoints that apply to a dermatology practice setting:

Regulatory compliance reference checklist for dermatology practice (informational):
1. State medical license — issued by individual state medical board under applicable medical practice act
2. DEA registration — required for prescribing controlled substances (e.g., certain pain medications used in procedural settings)
3. FDA compliance — device clearance for lasers and energy-based equipment; drug dispensing under applicable state pharmacy law
4. CLIA certification — required if the practice performs in-office laboratory testing including skin biopsy processing
5. OSHA compliance — bloodborne pathogen exposure controls under 29 CFR 1910.1030; hazard communication under 29 CFR 1910.1200
6. CMS enrollment — required for Medicare and Medicaid billing; provider NPI registration under HIPAA administrative simplification
7. HIPAA compliance — Privacy Rule (45 CFR Parts 160 and 164) and Security Rule governing protected health information

Patient access and rights — including insurance and coverage frameworks, patient rights in clinical encounters, teledermatology access, and guidance on locating board-certified practitioners.

The full scope of the content library, organized thematically, addresses the specialty as experienced by patients, clinicians, and policy stakeholders — from early skin conditions overview orientation through condition-specific detail, procedural explanation, and the framework governing who is qualified to provide care and under what regulatory authority.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)